{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,25]],"date-time":"2026-10-25T00:08:36Z","timestamp":1792886916712,"version":"4.5.0"},"reference-count":39,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2015,12,1]],"date-time":"2015-12-01T00:00:00Z","timestamp":1448928000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","internationaljournalofcardiology.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Cardiology"],"published-print":{"date-parts":[[2015,12]]},"DOI":"10.1016\/j.ijcard.2015.05.127","type":"journal-article","created":{"date-parts":[[2015,5,21]],"date-time":"2015-05-21T16:39:24Z","timestamp":1432226364000},"page":"25-29","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":166,"special_numbering":"C","title":["Safety profile of mineralocorticoid receptor antagonists: Spironolactone and eplerenone"],"prefix":"10.1016","volume":"200","author":[{"given":"Mitja","family":"Lainscak","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1260-1308","authenticated-orcid":false,"given":"Francesco","family":"Pelliccia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Rosano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristiana","family":"Vitale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Schiariti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cesare","family":"Greco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Speziale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo","family":"Gaudio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijcard.2015.05.127_bb0005","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1111\/j.1751-7176.2011.00511.x","article-title":"Aldosterone blockers (mineralocorticoid receptor antagonism) and potassium-sparing diuretics","volume":"13","author":"Epstein","year":"2011","journal-title":"J. Clin. Hypertens."},{"key":"10.1016\/j.ijcard.2015.05.127_bb0010","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1136\/bmj.38883.479549.2F","article-title":"Spironolactone and risk of upper gastrointestinal events: population based case-control study","volume":"33","author":"Verhamme","year":"2006","journal-title":"BMJ"},{"key":"10.1016\/j.ijcard.2015.05.127_bb0015","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1016\/S0140-6736(62)92199-2","article-title":"The effects of spironolactone and chlorthalidone on arterial pressure","volume":"1","author":"Cranston","year":"1962","journal-title":"Lancet"},{"key":"10.1016\/j.ijcard.2015.05.127_bb0020","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1001\/jama.1966.03110240051022","article-title":"Treatment of hypertension with spironolactone. Double-blind study","volume":"198","author":"Wolf","year":"1966","journal-title":"JAMA"},{"key":"10.1016\/j.ijcard.2015.05.127_bb0025","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.mce.2003.10.005","article-title":"The evolution of aldosterone antagonists","volume":"217","author":"Garthwaite","year":"2004","journal-title":"Mol. Cell. Endocrinol."},{"key":"10.1016\/j.ijcard.2015.05.127_bb0030","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1111\/j.1524-6175.2002.01510.x","article-title":"Eplerenone: a new aldosterone receptor antagonist. Are the FDA's restrictions appropriate?","volume":"4","author":"Sica","year":"2002","journal-title":"J. Clin. Hypertens."},{"key":"10.1016\/j.ijcard.2015.05.127_bb0035","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1016\/S0002-9149(96)00465-1","article-title":"Effectiveness of spironolactone added to an angiotensin-converting enzyme inhibitor and a loop diuretic for severe chronic congestive heart failure (the Randomized Aldactone Evaluation Study [RALES])","volume":"78","author":"Pitt","year":"1996","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/j.ijcard.2015.05.127_bb0040","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJM199909023411001","article-title":"The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators","volume":"341","author":"Pitt","year":"1999","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ijcard.2015.05.127_bb0045","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1056\/NEJMoa040135","article-title":"Rates of hyperkalaemia after publication of the randomized aldactone evaluation study","volume":"351","author":"Juurlink","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ijcard.2015.05.127_bb0050","first-page":"3","article-title":"Presidential address. I. Painting background. II. Primary aldosteronism, a new clinical syndrome","volume":"45","author":"Conn","year":"1955","journal-title":"J. Lab. Clin. Med."},{"key":"10.1016\/j.ijcard.2015.05.127_bb0055","doi-asserted-by":"crossref","first-page":"873","DOI":"10.3181\/00379727-115-29052","article-title":"Relationship of plasma aldadiene levels and antimineralocorticoid effects of spironolactone in the laboratory","volume":"115","author":"Kagawa","year":"1964","journal-title":"Proc. Soc. Exp. Biol. Med."},{"key":"10.1016\/j.ijcard.2015.05.127_bb0060","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1161\/01.HYP.0000179582.42830.1d","article-title":"Improvement in blood pressure with inhibition of the epithelial sodium channel in blacks with hypertension","volume":"46","author":"Saha","year":"2005","journal-title":"Hypertension"},{"key":"10.1016\/j.ijcard.2015.05.127_bb0065","doi-asserted-by":"crossref","first-page":"1762","DOI":"10.1345\/aph.1P338","article-title":"Spironolactone management of resistant hypertension","volume":"44","author":"Marrs","year":"2010","journal-title":"Ann. Pharmacother."},{"key":"10.1016\/j.ijcard.2015.05.127_bb0070","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1161\/CIRCULATIONAHA.108.778811","article-title":"Serum potassium and clinical outcomes in the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS)","volume":"118","author":"Pitt","year":"2008","journal-title":"Circulation"},{"key":"10.1016\/j.ijcard.2015.05.127_bb0075","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1016\/j.jacc.2013.04.086","article-title":"Safety and efficacy of eplerenone in patients at high risk for hyperkalemia and\/or worsening renal function: analyses of the EMPHASIS-HF study subgroups (Eplerenone in Mild Patients Hospitalization And SurvIval Study in Heart Failure)","volume":"62","author":"Eschalier","year":"2013","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.ijcard.2015.05.127_bb0080","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1161\/01.HYP.0000025146.19104.FE","article-title":"Efficacy of eplerenone added to renin\u2013angiotensin blockade in hypertensive patients","volume":"40","author":"Krum","year":"2002","journal-title":"Hypertension"},{"key":"10.1016\/j.ijcard.2015.05.127_bb0085","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/S0895-7061(02)02957-6","article-title":"Eplerenone, a selective aldosterone blocker, in mild-to-moderate hypertension","volume":"5","author":"Weinberger","year":"2002","journal-title":"Am. J. Hypertens."},{"key":"10.1016\/j.ijcard.2015.05.127_bb0090","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1161\/01.HYP.0000067463.13172.EA","article-title":"Effects of the selective aldosterone blocker eplerenone versus the calcium antagonist amlodipine in systolic hypertension","volume":"41","author":"White","year":"2003","journal-title":"Hypertension"},{"key":"10.1016\/j.ijcard.2015.05.127_bb0095","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.1161\/01.CIR.0000091405.00772.6E","article-title":"Effects of eplerenone, enalapril, and eplerenone\/enalapril in patients with essential hypertension and left ventricular hypertrophy: the 4E-left ventricular hypertrophy study","volume":"108","author":"Pitt","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.ijcard.2015.05.127_bb0100","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1016\/S0735-1097(03)00054-8","article-title":"Efficacy and tolerability of eplerenone and losartan in hypertensive black and white patients","volume":"41","author":"Flack","year":"2003","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.ijcard.2015.05.127_bb0105","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/S0002-9149(03)00461-2","article-title":"Assessment of the novel selective aldosterone blocker eplerenone using ambulatory and clinical blood pressurein patients with systemic hypertension","volume":"92","author":"White","year":"2003","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/j.ijcard.2015.05.127_bb0110","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1111\/j.1524-6175.2004.03146.x","article-title":"Efficacy and safety of the selective aldosterone blocker eplerenone in Japanese patients with hypertension: a randomized, double-blind, placebo-controlled, dose-ranging study","volume":"6","author":"Saruta","year":"2004","journal-title":"J. Clin. Hypertens."},{"key":"10.1016\/j.ijcard.2015.05.127_bb0115","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1016\/j.amjcard.2004.01.007","article-title":"Efficacy of eplerenone versus enalapril as monotherapy in systemic hypertension","volume":"93","author":"Williams","year":"2004","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/j.ijcard.2015.05.127_bb0120","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1016\/j.ahj.2004.12.005","article-title":"Effects of eplerenone versus losartan in patients with low-renin hypertension","volume":"150","author":"Weinberger","year":"2005","journal-title":"Am. Heart J."},{"key":"10.1016\/j.ijcard.2015.05.127_bb0125","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1161\/CIRCULATIONAHA.111.029892","article-title":"Effects of a novel aldosterone synthase inhibitor for treatment of primary hypertension: results of a randomized, double-blind, placebo- and active-controlled phase 2 trial","volume":"124","author":"Calhoun","year":"2011","journal-title":"Circulation"},{"key":"10.1016\/j.ijcard.2015.05.127_bb0130","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1038\/clpt.2011.227","article-title":"Mineralocorticoid receptor blocker eplerenone improves endothelial function and inhibits Rho-associated kinase activity in patients with hypertension","volume":"91","author":"Fujimura","year":"2012","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.ijcard.2015.05.127_bb0135","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1161\/CIRCHEARTFAILURE.112.000173","article-title":"Clinical benefit of eplerenone in patients with mild symptoms of systolic heart failure already receiving optimal best practice background drug therapy: analysis of the EMPHASIS-HF Study","volume":"6","author":"Krum","year":"2013","journal-title":"Circ. Heart Fail."},{"key":"10.1016\/j.ijcard.2015.05.127_bb0140","series-title":"The incidence and risk associated with serum potassium 4.0mmol\/L in patients with heart failure and a reduced left ventricular ejection fraction (HF-REF): results from the EMPHASIS-HF trial","author":"Pitt","year":"2012"},{"key":"10.1016\/j.ijcard.2015.05.127_bb0145","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1093\/eurjhf\/hfs067","article-title":"Eplerenone and new onset diabetes in patients with mild heart failure: results from the Eplerenone in Mild Patients Hospitalization and Survival Study in Heart Failure (EMPHASIS-HF)","volume":"14","author":"Preiss","year":"2012","journal-title":"Eur. J. Heart Fail."},{"key":"10.1016\/j.ijcard.2015.05.127_bb0150","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/j.mce.2011.06.025","article-title":"Molecular pharmacology of the mineralocorticoid receptor: prospects for novel therapeutics","volume":"350","author":"Kolkhof","year":"2012","journal-title":"Mol. Cell. Endocrinol."},{"key":"10.1016\/j.ijcard.2015.05.127_bb0155","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1056\/NEJMe1012547","article-title":"Aldosterone antagonists\u2014last man standing?","volume":"364","author":"Armstrong","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ijcard.2015.05.127_bb0160","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1161\/CIRCHEARTFAILURE.112.000115","article-title":"Association of spironolactone use with all-cause mortality in heart failure: a propensity scored cohort study","volume":"6","author":"Lund","year":"2013","journal-title":"Circ. Heart Fail."},{"key":"10.1016\/j.ijcard.2015.05.127_bb0165","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1177\/2040622311429891","article-title":"Eplerenone: is it time to add this drug to current heart failure therapy?","volume":"3","author":"Pitt","year":"2012","journal-title":"Ther. Adv. Chron. Dis."},{"key":"10.1016\/j.ijcard.2015.05.127_bb0170","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1007\/s00125-004-1510-8","article-title":"Spironolactone impairs endothelial function and heart rate variability in patients with type 2 diabetes","volume":"47","author":"Davies","year":"2004","journal-title":"Diabetologia"},{"key":"10.1016\/j.ijcard.2015.05.127_bb0175","doi-asserted-by":"crossref","first-page":"920","DOI":"10.5114\/aoms.2014.46212","article-title":"Potential drug\u2013drug interactions in hospitalized patietns with chronic heart failure and chronic obstructive pulmonary disease","volume":"10","author":"Roblek","year":"2014","journal-title":"Arch. Med. Sci."},{"key":"10.1016\/j.ijcard.2015.05.127_bb0180","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1093\/eurheartj\/ehq502","article-title":"On behalf of the PEARL-HF investigators. Evaluation of the efficacy and safety of RLY5016, a polymeric potassium binder in a double-blind placebo-controlled study in patients with chronic heart failure (the PEARL-HF) trial","volume":"32","author":"Pitt","year":"2011","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.ijcard.2015.05.127_bb0185","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1007\/s40265-013-0098-z","article-title":"Eplerenone: a review of its use in patients with chronic systolic heart failure and mild symptoms","volume":"73","author":"Dhillon","year":"2013","journal-title":"Drugs"},{"key":"10.1016\/j.ijcard.2015.05.127_bb0190","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1093\/eurjhf\/hfs033","volume":"14","author":"McMurray","year":"2012","journal-title":"Eur. J. Heart Fail."},{"key":"10.1016\/j.ijcard.2015.05.127_bb0195","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1177\/0091270005275894","article-title":"Pharmacokinetics of eplerenone after single and multiple dosing in subjects with and without renal impairment","volume":"45","author":"Ravis","year":"2005","journal-title":"J. Clin. Pharmacol."}],"container-title":["International Journal of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167527315011900?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167527315011900?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,22]],"date-time":"2018-09-22T08:23:36Z","timestamp":1537604616000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0167527315011900"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,12]]},"references-count":39,"alternative-id":["S0167527315011900"],"URL":"https:\/\/doi.org\/10.1016\/j.ijcard.2015.05.127","relation":{},"ISSN":["0167-5273"],"issn-type":[{"value":"0167-5273","type":"print"}],"subject":[],"published":{"date-parts":[[2015,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safety profile of mineralocorticoid receptor antagonists: Spironolactone and eplerenone","name":"articletitle","label":"Article Title"},{"value":"International Journal of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijcard.2015.05.127","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Ireland Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}